cytarabine has been researched along with decitabine in 147 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (12.24) | 18.7374 |
| 1990's | 10 (6.80) | 18.2507 |
| 2000's | 8 (5.44) | 29.6817 |
| 2010's | 75 (51.02) | 24.3611 |
| 2020's | 36 (24.49) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, PD; McNamara, DJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Laliberté, J; Marquez, VE; Momparler, RL | 1 |
| Momparler, LF; Momparler, RL; Onetto-Pothier, N | 1 |
| Pískala, A; Veselý, J | 1 |
| Moriconi, WJ; Slavik, M; Taylor, S | 1 |
| Holliday, R | 1 |
| Bhalla, K; Gleyzer, M; Grant, S | 1 |
| Colombo, T; D'Incalci, M; Rossi, C | 1 |
| Gyger, M; Momparler, LF; Momparler, RL; Onetto, N | 1 |
| Antonsson, BE; Avramis, VI; Holcenberg, JS; Nyce, J | 1 |
| Jones, PA; Michalowsky, LA | 1 |
| Pfeifer, GP; Steigerwald, SD | 1 |
| Colly, LP; Lurvink, E; Richel, DJ; Willemze, R | 1 |
| Momparler, LF; Momparler, RL | 1 |
| Momparler, LF; Momparler, RL; Samson, J | 1 |
| Jones, PA; Taylor, SM | 1 |
| Benoit, P; Demers, J; Lin, K; Momparler, LF; Momparler, RL; Raymond, R; Rivard, GE | 1 |
| Ellims, PH | 1 |
| Bouchard, J; Chabot, GG; Momparler, RL | 1 |
| Chabot, GG; Momparler, RL | 1 |
| Honders, WH; Landegent, JE; Ruiz van Haperen, VW; Stegmann, AP; Willemze, R | 1 |
| Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Hagemeijer, A; Hoebee, B; Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Honders, MW; Kester, MG; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Côté, S; Momparler, RL | 1 |
| Catapano, CV; Colombo, T; Conter, V; Damia, G; Gervasoni, M; Giudici, G; Limonta, M; Liso, V; Masera, G; Specchia, G | 1 |
| Cournoyer, D; Eliopoulos, N; Momparler, RL | 1 |
| Beauséjour, C; Eliopoulos, N; Momparler, RL | 1 |
| Beauséjour, CM; Eliopoulos, N; Le, NL; Momparler, L; Momparler, RL | 1 |
| Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML | 1 |
| Beauséjour, CM; Gagnon, J; Momparler, RL; Primeau, M | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Broekhuizen, AJ; Creutzig, U; Gibson, BE; Hubeek, I; Kaspers, GJ; Peters, GJ; Sargent, J | 1 |
| Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A | 1 |
| Chen, R; Garcia-Manero, G; Issa, JP; Jelinek, J; Qin, T; Yang, AS; Youssef, EM | 1 |
| Karp, J | 1 |
| Rogers, BB | 1 |
| Breiling, A; Lyko, F; Musch, T; Oz, Y | 1 |
| Karaman, R | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Advani, A; Copelan, E; Ebrahem, Q; Gu, X; Hu, Z; Kalaycio, M; Link, KA; Maciejewski, J; Mahfouz, RZ; Mulloy, JC; Negrotto, S; Ng, KP; Radivoyevitch, T; Saunthararajah, Y; Sekeres, M; Sobecks, R | 1 |
| Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Y; Zhang, Z | 1 |
| Arthur, C; Buckstein, R; Cermak, J; Chou, WC; Delaunay, J; Dmoszynska, A; Faderl, S; Gau, JP; Kantarjian, HM; Kuo, CY; Lysák, D; Mayer, J; Mazur, G; Minden, M; Oriol, A; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Roboz, GJ | 1 |
| Chang, C; Fei, C; Gu, S; Guo, J; Li, X; Zhang, X; Zhang, Y; Zhao, Y | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Atenafu, EG; Brandwein, JM; Craddock, KJ; Gupta, V; Kennedy, JA; Lipton, JH; Messner, HA; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Côté, S; Momparler, LF; Momparler, RL | 1 |
| Sekeres, MA | 1 |
| Kearns, P; Leonard, SM; Perry, T; Woodman, CB | 1 |
| Arthur, C; Berrak, E; Delaunay, J; Jones, M; Kantarjian, HM; Li, Y; Mayer, J; Mazur, G; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Cui, GX; Wu, WZ; Zhang, YP | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Erba, HP | 1 |
| Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y | 1 |
| Ford, LA; Gandhi, S; Griffiths, EA; Gupta, N; Miller, A; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Tan, H; Wang, C; Xie, B; Xu, J; Yu, B; Zheng, R | 1 |
| Carter, BZ; Dai, M; Ding, B; Jiang, L; Jiang, X; Liang, S; Liu, Q; Meng, F; Wang, Z; Ye, J; Yin, C; Yu, G; Zhang, Y; Zhao, Q; Zhong, Q | 1 |
| Chang, C; Chao, X; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH | 1 |
| Bainschab, A; Greinix, HT; Krause, R; Quehenberger, F; Sill, H; Wölfler, A; Zebisch, A | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y | 1 |
| Gerds, AT; Mukherjee, S | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bhalla, K; Boddu, PC; Cortes, JE; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Ohanian, M; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Verstovsek, S; Wierda, WG | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Liu, P; Zhang, H; Zhou, S | 1 |
| Helleday, T; Henter, JI; Herold, N; Kutzner, J; Myrberg, IH; Olsen, TK; Paulin, CBJ; Rudd, SG; Sanjiv, K; Schaller, T | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Chen, SN; Fu, ZZ; Li, WY; Qiu, HY; Sun, AN; Wang, Y; Wu, DP | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K | 1 |
| DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH | 1 |
| Hong, M; Huang, J; Li, J; Lian, Y; Qian, S; Wu, Y; Zhang, X; Zhao, H; Zhao, X; Zhu, Y | 1 |
| Becktell, K; Burke, MJ; Houser, K | 1 |
| Feng, YF; Fu, CC; Han, Y; Li, WY; Ma, X; Qiu, HY; Sun, AN; Tang, XW; Wu, DP | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Chen, RA; Chen, Y; Ji, YR; Li, GH; Liu, C; Liu, L; Qin, WW; Wang, WQ; Zhou, NC | 1 |
| Konopleva, M; Letai, A | 1 |
| Al Yacoub, R; Cronin, TL; Griffiths, EA; Miller, A; Ontiveros, EP; Thompson, JE; Vachhani, P; Wang, ES; Zhang, F | 1 |
| Gibson, B; Huang, F; Kearns, P; Moreno, L; Nakahara, S; Nemat, S; Nysom, K; Parasrampuria, DA; Reinhardt, D; Zhou, W; Zwaan, CM | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Hu, Y; Huang, H; Jin, A; Jin, M; Luo, Y; Tan, Y; Wei, G; Wu, W; Yang, L; Yu, J | 1 |
| Guo, X; Zhang, X | 1 |
| Cao, YP; Li, JG; Zhang, JL | 1 |
| Baker, SD; Behbehani, G; Bhatnagar, B; Blachly, J; Blum, W; Buelow, DR; Byrd, JC; Garzon, R; Jeon, JY; Klisovic, RB; Mims, AS; Phelps, M; Vasu, S; Walker, AR; Zhao, Q | 1 |
| Flaishon, L; Rowe, JM; Stone, A; Yakar, RB; Zukerman, T | 1 |
| Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH | 1 |
| Jing, Y; Li, Y; Lv, N; Wang, L; Xu, Q; Yu, L | 1 |
| Dong, Y; Hu, J; Li, J; Li, X; Li, Y; Ren, R; Wu, W; Zhang, Y; Zhu, H | 1 |
| Chang, C; He, Q; Li, X; Song, L; Su, J; Tao, Y; Wu, D; Wu, L; Xiu, C; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Bian, Y; Huang, C; Ma, S; Ma, W; Miao, L; Miao, M; Xia, F; Yu, D | 1 |
| Becker, PS; Buckley, SA; Estey, EH; Halpern, AB; Hendrie, PC; Oehler, VG; Othus, M; Palmieri, R; Percival, MM; Scott, BL; Walter, RB | 1 |
| Antunovic, P; Cammenga, J; Deneberg, S; Derolf, ÅR; Eriksson, A; Höglund, M; Juliusson, G; Lazarevic, V; Lehmann, S; Lorenz, F; Möllgård, L; Ölander, E; Österroos, A; Uggla, B; Wennström, L | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Huang, L; Hui, Y; Li, Y; Mao, X; Shang, Z; Wang, Y; Wang, Z; Wei, J; Xiao, M; Zhang, D; Zheng, L | 1 |
| Hong, M; Li, JY; Miao, Y; Qian, SX; Qiu, HR; Sun, Q; Yang, H; Zhu, H; Zhu, Y | 1 |
| Luo, ZQ; Pan, PJ | 1 |
| Li, TT; Ran, XH; Sun, L; Wang, LJ; Wu, XF | 1 |
| Liu, C; Shao, Z; Sun, Y; Wu, C | 1 |
| Beutel, G; Eder, M; Gabdoulline, R; Gohring, G; Heuser, M; Koenecke, C; Krauter, J; Markel, D; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Trummer, A | 1 |
| Han, Y; Meng, T; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D; Xu, Y; Xue, S; Yao, Y; Zhang, Y | 1 |
| Chen, G; Fang, M; Gao, S; Gao, X; Li, X; Li, Y; Liu, H; Liu, Z; Luo, J; Ma, Y; Shen, J; Sun, K; Wang, L; Wang, X; Wei, X; Yang, L; Yu, L; Zhang, Y; Zhou, W | 1 |
| Anderson, JT; Baker, SD; Buelow, DR; Gibson, AA; Goodwin, EA; Hu, S; Lamba, JK; Pounds, SB; Shi, L; Sparreboom, A | 1 |
| He, J; Wang, L; Yan, X | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Gangat, N; Tefferi, A | 1 |
| Diao, S; DiNardo, C; DiPippo, AJ; Konopleva, M; Maiti, A; Nichols, ED; Ning, J; Qiao, W | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Cao, L; Chen, SS; Hong, M; Li, JY; Qian, SX; Qiao, C; Sun, Q; Wu, WZ; Xie, Y | 1 |
| Allis, CD; Chen, H; Chen, X; Lu, C; Majewski, J; Rajagopalan, KN; Weinberg, DN | 1 |
| Zhang, X | 1 |
| Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X | 1 |
| Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME | 1 |
| Alvarado, Y; Bivins, CA; Borthakur, G; Daver, NG; DiNardo, CD; Guerrero, JA; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Konopleva, MY; Maduike, RE; Maiti, A; Montalbano, KS; Ning, J; Pemmaraju, N; Pierce, S; Qiao, W; Rausch, CR; Ravandi, F; Short, NJ; Vaughan, K; Wade, A; Yilmaz, M | 1 |
| Aldrich, J; Alvarado, Y; Borthakur, G; Daver, N; DiNardo, C; Garcia-Manero, G; Kadia, T; Ohanian, M; Patel, K; Pemmaraju, N; Ravandi, F; Senapati, J; Shoukier, M; Wang, X | 1 |
| Bhojwani, D; Brown, P; Burke, MJ; Chang, BH; Chi, YY; Colace, SI; Florendo, E; Gossai, N; Heimbruch, K; Hermiston, ML; Heym, K; Hutchinson, RJ; Huynh, VT; Kaplan, JA; Malvar, J; Mody, R; O'Brien, TA; Place, AE; Pommert, L; Pulakanti, K; Rao, S; Schafer, ES; Shaw, PH; Sposto, R; Stelloh, C; Wayne, A; Ziegler, DS | 1 |
| Cheng, S; Ding, X; Gao, L; Hu, S; Hu, Y; Li, B; Li, Z; Ling, J; Lu, J; Lu, Q; Pan, J; Ribeiro, RC; Wang, J; Wang, Y; Xiao, P; Zheng, J | 1 |
| Bai, J; Pei, Z; Song, Q; Wang, H; Wang, J; Wu, H; Zhang, B | 1 |
| Bhojwani, D; Burke, MJ; Chao, K; Colace, SI; Doan, A; Gossai, NP; Guinipero, T; Hilsenbeck, SG; Hinson, A; Jo, E; Kaplan, JA; Otterson, D; Pommert, L; Schafer, ES; Stevens, AM; Wayne, AS | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Dong, CX; Hou, YF; Huang, YJ; Kang, JM; Qi, K; Yang, LH; Zhang, JH; Zhang, YF | 1 |
| Assouline, S; Bergeron, J; Borden, KLB; Cocolakis, E; Culjkovic-Kraljacic, B; Gasiorek, J; Lambert, C; Szlachtycz, D; Yee, K; Zakaria, C | 1 |
| Gao, XN; Jing, Y; Li, MY; Li, YF; Liu, DH; Su, YF; Wang, A; Wang, J; Wang, YZ; Xu, L; Zhang, LL; Zheng, X | 1 |
| Cao, L; Hong, M; Jiang, ZQ; Li, JY; Liu, WJ; Qian, SX; Sun, Q; Zhu, Y | 1 |
18 review(s) available for cytarabine and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Therapy, Combination; Fluorouracil; Humans; Methotrexate; Neoplasms; Thymidine | 1982 |
Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Drug Resistance; Gemcitabine; Humans | 1999 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Current treatment of acute myeloid leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Precision Medicine; Stem Cell Transplantation | 2012 |
The euphoria of hypomethylating agents in MDS and AML: is it justified?
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; Endpoint Determination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Decitabine. Acute myeloid leukaemia: no progress.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Patient Selection; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Young Adult | 2016 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
BCL-2 inhibition in AML: an unexpected bonus?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
[Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2019 |
Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin | 2020 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
23 trial(s) available for cytarabine and decitabine
| Article | Year |
|---|---|
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2012 |
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Decision Making; Decitabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Palliative Care; Patient Participation; Remission Induction; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetic Analysis; Decitabine; Female; Humans; Internationality; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Risk Factors; Treatment Outcome | 2014 |
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; DNA Methylation; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperglycemia; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vincristine; Young Adult | 2014 |
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome | 2015 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Decitabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2019 |
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2019 |
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Decitabine; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pilot Projects; Protein Kinase Inhibitors; Pyrimidines | 2020 |
Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Consolidation Chemotherapy; Cytarabine; Decitabine; Disease-Free Survival; Female; Fetal Blood; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Survival Rate | 2019 |
The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Treatment Outcome | 2019 |
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Treatment Outcome | 2020 |
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Topics: Aclarubicin; Adolescent; Adult; Aminopyridines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome; Young Adult | 2020 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Lymphoma; Vorinostat | 2022 |
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Vidarabine; Vorinostat | 2022 |
Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Eukaryotic Initiation Factor-4E; Glucuronosyltransferase; Hedgehog Proteins; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Ribavirin; Uridine Diphosphate; Zinc Finger Protein GLI1 | 2023 |
Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
106 other study(ies) available for cytarabine and decitabine
| Article | Year |
|---|---|
Synthesis and antitumor activity of fluorine-substituted 4-amino-2(1H)-pyridinones and their nucleosides. 3-Deazacytosines.
Topics: Animals; Antimetabolites, Antineoplastic; Cytosine; Drug Evaluation, Preclinical; Indicators and Reagents; Leukemia L1210; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Spectrophotometry; Structure-Activity Relationship | 1987 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Topics: Antineoplastic Agents; Azacitidine; Azepines; Cytarabine; Cytidine; Cytidine Deaminase; Deamination; Decitabine; Humans; Kinetics; Pyrimidine Nucleosides; Tetrahydrouridine | 1992 |
Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
Topics: Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; DNA; Humans; Leukemia; Methylation; Phenotype; Tumor Cells, Cultured | 1990 |
Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Line; Cell Survival; Cytarabine; Decitabine; Drug Evaluation, Preclinical; Kinetics; Leukemia L1210; Leukocyte Count; Male; Mice; Mice, Inbred DBA; Nucleosides; Phosphorylation; Thymidine | 1986 |
3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Topics: 3-Deazauridine; Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Evaluation; Drug Synergism; Galactosamine; Humans; Kinetics; Leukemia; Neoplasms; Thymidine; Uridine | 1986 |
Strong effects of 5-azacytidine on the in vitro lifespan of human diploid fibroblasts.
Topics: 5-Methylcytosine; Azacitidine; Cell Division; Cell Line; Cell Survival; Cytarabine; Cytosine; Decitabine; DNA; Fibroblasts; Humans; Methylation | 1986 |
Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.
Topics: Azacitidine; Cell Division; Cell Line; Colony-Forming Units Assay; Cytarabine; Decitabine; Deoxycytidine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1986 |
Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Drug Interactions; Leukemia L1210; Male; Mice; Statistics as Topic | 1986 |
In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
Topics: Adult; Azacitidine; Cells, Cultured; Child; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Replication; DNA, Neoplasm; Drug Resistance; Humans; In Vitro Techniques; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Thymidine Kinase | 1987 |
Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.
Topics: Azacitidine; Cell Line; Cytarabine; Decitabine; Deoxycytidine Kinase; DNA; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance; Humans; Lymphoid Tissue; Methylation; Phosphotransferases | 1987 |
Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Line; Cell Nucleus; Cytarabine; Cytosine; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Resistance; Methylation; Mice | 1987 |
Variable DNA methylation changes during differentiation of human melanoma cells.
Topics: Aphidicolin; Azacitidine; Cell Differentiation; Cell Division; Chromatography, High Pressure Liquid; Cytarabine; Decitabine; Diterpenes; DNA; DNA, Neoplasm; Humans; Hydroxyurea; Methylation; Monophenol Monooxygenase; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1988 |
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Decitabine; DNA; Dose-Response Relationship, Drug; Female; Leukemia, Myeloid; Rats; Rats, Inbred BN; Time Factors | 1988 |
Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
Topics: 3-Deazauridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line; Cytarabine; Decitabine; Drug Interactions; Drug Resistance; Drug Screening Assays, Antitumor; Leukemia L1210; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Tumor Cells, Cultured | 1989 |
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; DNA, Neoplasm; Leukemia L1210; Male; Methylation; Mice; Mice, Inbred BALB C; Mice, Inbred DBA | 1984 |
Cellular differentiation, cytidine analogs and DNA methylation.
Topics: Adipose Tissue; Animals; Azacitidine; Cell Differentiation; Cells, Cultured; Cytarabine; Cytidine; Decitabine; Deoxycytidine; DNA; DNA (Cytosine-5-)-Methyltransferases; Methylation; Methyltransferases; Mice; Muscles; Structure-Activity Relationship | 1980 |
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation; Hematopoietic System; Humans; Leukemia; Male | 1981 |
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Topics: 3-Deazauridine; Adult; Arabinofuranosyluracil; Azacitidine; Cytarabine; Cytidine Deaminase; Cytosine; Decitabine; Humans; Kinetics; Liver; Nucleoside Deaminases; Substrate Specificity; Thymidine | 1983 |
Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
Topics: Animals; Azacitidine; Brain Neoplasms; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Kinetics; Leukemia L1210; Male; Mice; Mice, Inbred Strains | 1984 |
Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity.
Topics: Animals; Azacitidine; Base Sequence; Cytarabine; Decitabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance; Leukemia, Experimental; Molecular Sequence Data; Phosphorylation; Rats; Recombinant Fusion Proteins; RNA, Messenger; Transfection; Tumor Cells, Cultured | 1995 |
De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Topics: Animals; Antineoplastic Agents; Azacitidine; Blotting, Southern; Cell Line; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; Gene Expression; Kinetics; Leukemia, Experimental; Polymerase Chain Reaction; Polymorphism, Genetic; Rats; Restriction Mapping; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Topics: Animals; Antineoplastic Agents; Azacitidine; Base Sequence; Chromosome Aberrations; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Rats; Translocation, Genetic; Tumor Cells, Cultured | 1995 |
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Topics: Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Binding, Competitive; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Rats; Rats, Inbred BN; Tumor Cells, Cultured | 1993 |
Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzofurans; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; Cyclohexanecarboxylic Acids; Cyclohexenes; Cytarabine; Decitabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Duocarmycins; Humans; Indoles; Lung Neoplasms; Time Factors; Tumor Cells, Cultured | 1993 |
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells.
Topics: Antineoplastic Agents; Azacitidine; Blast Crisis; Cytarabine; Decitabine; DNA, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1993 |
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Topics: 3T3 Cells; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA, Complementary; Drug Resistance; Enzyme Inhibitors; Fibroblasts; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Mice; Phenotype; Retroviridae; Tetrahydrouridine | 1998 |
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA Modification Methylases; Drug Evaluation; Drug Resistance; Enzyme Inhibitors; Flow Cytometry; Gene Transfer Techniques; Genetic Vectors; Green Fluorescent Proteins; Humans; Leukemia; Luminescent Proteins; Retroviridae; Transgenes | 2001 |
Somatic recombination: a major genotoxic effect of two pyrimidine antimetabolitic chemotherapeutic drugs in Drosophila melanogaster.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drosophila melanogaster; Female; Male; Molecular Structure; Mutagenicity Tests; Recombination, Genetic | 2002 |
Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Topics: 3T3 Cells; Animals; Azacitidine; Cell Death; Cell Line; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Dose-Response Relationship, Drug; Gemcitabine; Genetic Vectors; Humans; Mice; Phenotype; Phosphorylation; Retroviridae; Thymidine Kinase; Tumor Cells, Cultured | 2002 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Aphidicolin; Azacitidine; Child; Cyclin-Dependent Kinases; Cytarabine; Decitabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Nucleic Acid Synthesis Inhibitors; Ribonucleotide Reductases | 2005 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome | 2006 |
Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; DNA, Neoplasm; HL-60 Cells; Humans; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Advances in the management of acute myeloid leukemia in older adult patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Practice Guidelines as Topic; Prognosis; Quality of Life; Social Support; Stem Cell Transplantation | 2010 |
Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors.
Topics: Azacitidine; Carcinoma, Embryonal; Caspase 7; Caspase Inhibitors; Cell Differentiation; Cell Line, Tumor; Cytarabine; Decitabine; DNA Damage; DNA Methylation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Neurons; Octamer Transcription Factor-3; Polycomb-Group Proteins; Protein Processing, Post-Translational; Protein Stability; Repressor Proteins; Stem Cell Factor | 2010 |
Prodrugs of aza nucleosides based on proton transfer reaction.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Design; Hydrogen Bonding; Kinetics; Myelodysplastic Syndromes; Nucleosides; Prodrugs; Protons; Thermodynamics | 2010 |
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Differentiation; Cytarabine; Decitabine; DNA Damage; Electrophoresis, Polyacrylamide Gel; Epigenesis, Genetic; Genes, p53; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Transplantation, Heterologous | 2011 |
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Decitabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Ribosomal Proteins; Risk Factors; Treatment Outcome; Young Adult | 2012 |
Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.
Topics: Adult; Aged; Apoptosis; Azacitidine; Bone Marrow Cells; Cells, Cultured; Cytarabine; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Humans; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Survival; Tumor Protein p73; Tumor Suppressor Proteins | 2013 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Combined Modality Therapy; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Registries; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |
Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Approval; HL-60 Cells; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
[Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2014 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cytarabine; Decitabine; Disease-Free Survival; Female; Harringtonines; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2015 |
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Retrospective Studies | 2015 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Time Factors | 2016 |
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Virus Diseases | 2016 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Histocompatibility; HLA Antigens; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation | 2017 |
A New Style of Transplantation May Gain Points When Treating Older Patients with Acute Myeloid Leukemia.
Topics: Aged; Cytarabine; Decitabine; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Stem Cells | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Proportional Hazards Models; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Computational Biology; Cytarabine; Databases, Genetic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Ontology; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Annotation | 2017 |
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytarabine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid; Monomeric GTP-Binding Proteins; Mutation; Nervous System Malformations; SAM Domain and HD Domain-Containing Protein 1; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2018 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
[Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Topics: Alzheimer Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2017 |
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
[Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2018 |
Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Down Syndrome; Granulocyte Colony-Stimulating Factor; Humans; Infant; Leukemia, Myeloid, Acute; Male; Vidarabine; Vorinostat | 2019 |
[Comparison of the efficacy of decitabine combined with micro-transplantation or priming regimen as consolidation treatment for older patients with acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Treatment Outcome | 2018 |
[Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Treatment Outcome | 2018 |
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2018 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Siblings; Transplantation, Haploidentical; Treatment Outcome | 2019 |
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Genes, Modifier; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2020 |
A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
Topics: Aclarubicin; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2020 |
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2020 |
Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
[Efficacy of Small Dose HAG Regimen Combined with Decitabine in Treatment of Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Survival Rate; Treatment Outcome | 2020 |
[Clinical Comparation of Two Kinds of Chemotherapy Regimens in the Treatment of Patients with MDS-RAEB/AML-MRC].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2020 |
Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2020 |
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Sulfonamides; Tumor Lysis Syndrome | 2021 |
Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Survival Analysis | 2020 |
DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Child; Clinical Trials, Phase III as Topic; Cytarabine; Datasets as Topic; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenetic Repression; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Organic Cation Transport Proteins; Progression-Free Survival; Randomized Controlled Trials as Topic; Symporters; Young Adult | 2021 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Fluid Therapy; Humans; Hydroxyurea; Incidence; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukocytosis; Male; Middle Aged; Phosphate-Binding Proteins; Phosphorus; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Sulfonamides; Tumor Lysis Syndrome; Urate Oxidase; Uric Acid | 2021 |
Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Tumor Suppressor Protein p53 | 2020 |
Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Cell Line; Chromatin; CRISPR-Cas Systems; Cytarabine; Decitabine; Epigenesis, Genetic; Gene Editing; Histone-Lysine N-Methyltransferase; Histones; Humans; Lysine; Mesenchymal Stem Cells; Methylation; Mice; Mutation; Neoplasm Proteins; Neoplasms; Phenotype; Protein Isoforms; Protein Processing, Post-Translational; Repressor Proteins; Transcriptome | 2021 |
Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomal Proteins, Non-Histone; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins; Poly-ADP-Ribose Binding Proteins; Treatment Outcome | 2021 |
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clofarabine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleophosmin; Treatment Outcome | 2021 |
Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Propensity Score; Sulfonamides | 2021 |
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Prognosis | 2022 |
Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases.
Topics: Abnormal Karyotype; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberrations; Chromosome Deletion; Cytarabine; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2022 |
Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation.
Topics: Adult; Aged; Aminopyridines; Antimetabolites, Antineoplastic; Benzamides; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
[Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2022 |
[Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
Topics: Aged; Aged, 80 and over; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Prognosis; Retrospective Studies | 2023 |